Home World News Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with... World News Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 254 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for... September 23, 2026 How Can I Get the Latest Cancer Drug? October 14, 2020 Food for thought: new insights into how chemotherapy causes cachexia June 15, 2022 Breaking News: The Healthcare Marketplace Re-opens TODAY! February 15, 2021 Load more HOT NEWS Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... Reflections from our chief scientist: The rise of the whole organism Lo que deben saber las personas con cáncer de mama y...
